Company Overview and News

9
TESARO Announces Data Presentations at ESMO 2018 Congress

50m globenewswire
MUNICH, Germany, Oct. 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today summarized updated Phase 1 GARNET data of TSR-042 (anti-PD-1 antibody) in patients with recurrent or advanced microsatellite instability high (MSI-H) endometrial cancer presented during the European Society for Medical Oncology (ESMO) Congress. Blinded, pooled interim safety data from the Phase 3 PRIMA trial of niraparib in patients with first-line ovarian cancer regardless of biomarker status were also presented in a poster discussion session and additional data from the QUADRA trial of niraparib for treatment of late-line ovarian cancer beyond BRCAmut were presented in a poster display.
TSRO

9
TESARO Announces Data Presentations at the ESMO 2018 Congress

2018-10-09 globenewswire
WALTHAM, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from six abstracts will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany.
TSRO

16
Do Options Traders Know Something About Tesaro (TSRO) Stock We Don't?

2018-10-05 zacks
Investors in Tesaro, Inc. (TSRO - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 16, 2018 $55.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
TSRO WBA LMAT YY

13
Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC

2018-10-03 zacks - 1
Clovis Oncology, Inc. (CLVS - Free Report) announced that the FDA has granted Breakthrough Therapy designation for its cancer drug, Rubraca (rucaparib). The designation was granted for treating BRCA1/2 mutated metastatic castration resistant prostate cancer (mCRPC), based on initial data from phase II TRITON2 study. Currently, the study is evaluating the drug in mCRPC patients with BRCA mutations and ATM mutations.
TSRO AZN AZN CLVS

31
Here's Why J&J (JNJ) is a Good Bet in a Troubled Market

2018-10-03 zacks
In a bull market, it is easy to pick stocks and stay invested as shares of the majority of the listed companies move up on strong macroeconomic factors as well as positive sentiments. However, stock picking gets difficult in a bear market. A wrong choice can severely impact investors’ portfolio as had been the case at the time of the 2008 market crash.
TSRO JNJ ABBV ABBV

9
TESARO Announces Data Presentations at the SITC 2018 Annual Meeting

2018-10-01 globenewswire
WALTHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from a total of five abstracts will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 7-11, 2018 in Washington, D.C.
TSRO

47
Verastem Declines On Its Much-Touted Catalyst, Is It Worth Buying Now?

2018-09-26 seekingalpha - 2
Verastem had its ups and downs in 2018, but they've finally gotten their first drug approval in non-Hodgkin lymphoma.
TSRO NVCR AZN VSTM ABBV ABBV

9
3 Ways to Unpack Some Hidden Treasure in Tesaro Stock

2018-09-25 investorplace
After a difficult 2018, investors may consider adding Tesaro (NASDAQ:TSRO) stock, an oncology-focused biopharmaceutical company, to their portfolio for the rest of the year. Specifically, there are three bullish plays in TSRO stock that I want to share with you, as each play could lead to impressive profits.
TSRO GILD

80
Deciphera Pharmaceuticals: Will This ASCO Winner Repeat At ESMO?

2018-09-20 seekingalpha - 1
The valuation gap with larger competitor Blueprint Medicines appears enticing, even after the latter's recent decline.
DCPH TSRO SHPG BPMC AMGN MRK SPPI AGIO HRTX PFE GSK

9
TESARO Announces Participation at Two Investor Conferences

2018-09-19 globenewswire
WALTHAM, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
TSRO

10
Options Traders Expect Huge Moves in Tesaro (TSRO) Stock

2018-09-17 zacks - 1
Investors in Tesaro, Inc. (TSRO - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 18, 2019 $45.00 Call had some of the highest implied volatility of all equity options today.
TSRO

25
Pharma/Biotech Stocks to Watch This Prostate Cancer Month

2018-09-14 zacks - 1
September is observed as National Prostate Cancer Month to raise awareness about the disease, which is the leading cause of death in men, second only to skin cancer in the United States. A light blue ribbon is used as a symbol to raise awareness about prostate cancer.
4503 TSRO ALPMY AZN ECYT CY ALPMF AZN ABBV PFE ABBV SNY

15
2 Approaches To BioPharma: Interview With TPT Collaborators Amit Ghate And Zach Hartman

2018-09-10 seekingalpha - 4
Thanks for joining us today! Welcome to Dr Zach Hartman and Amit Ghate, two well-known analysts on SeekingAlpha, and very luckily for us here at the Total Pharma Tracker, our two outstanding collaborators.
VTL MNKD TSRO EXEL NVCR GERN XNET TLRY BGNE AERI WATT RDUS

10
TSRO / TESARO, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-09-10 sec.gov - 1
SCHEDULE 13G Amendment No. 7 TESARO INC COMMON STOCK Cusip #881569107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #881569107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 321,195 Item 6: 0 Item 7: 2,310,209 Item 8: 0 Item 9: 2,310,209 Item 11: 4.201% Item 12: HC Cusip #881569107 Item 1: Reporting Person - Abigail P.
TSRO

9
TSRO / TESARO, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-09-10 sec.gov
SCHEDULE 13G Amendment No. 7 TESARO INC COMMON STOCK Cusip #881569107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #881569107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 321,195 Item 6: 0 Item 7: 2,310,209 Item 8: 0 Item 9: 2,310,209 Item 11: 4.201% Item 12: HC Cusip #881569107 Item 1: Reporting Person - Abigail P.
TSRO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 881569107